Follistatin-Like 1 Promotes Bleomycin-Induced Pulmonary Fibrosis through the Transforming Growth Factor Beta 1/Mitogen-Activated Protein Kinase Signaling Pathway

被引:20
作者
Jin, Yan-Kun [1 ,2 ,3 ]
Li, Xiao-He [4 ]
Wang, Wang [2 ,5 ]
Liu, Jie [2 ,5 ]
Zhang, Wei [2 ,5 ]
Fang, Yin-Shan [4 ]
Zhang, Zhi-Fei [2 ,5 ]
Dai, Hua-Ping [3 ]
Ning, Wen [4 ]
Wang, Chen [2 ,3 ]
机构
[1] Capital Med Univ, Beijing Chao Yang Hosp, Dept Resp & Crit Care Med, Beijing 100020, Peoples R China
[2] Capital Med Univ, Dept Resp Dis, Beijing Key Lab Resp & Pulm Circulat Disorders, Beijing 100020, Peoples R China
[3] Capital Med Univ, Dept Resp Dis, Beijing 100020, Peoples R China
[4] Nankai Univ, Coll Life Sci, Dept Life Sci, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China
[5] Capital Med Univ, Dept Physiol & Pathophysiol, Beijing 100069, Peoples R China
基金
中国国家自然科学基金;
关键词
Follistatin-Like; 1; Mitogen-Activated Protein Kinase; Pulmonary Fibrosis; Transforming Growth Factor Beta 1; P38 MAPK INHIBITOR; LUNG; PATHOGENESIS; FIBROBLASTS; APOPTOSIS; THERAPY; DISEASE; FSTL1; MODEL; MICE;
D O I
10.4103/0366-6999.238151
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Follistatin-like 1 (FSTL1) is a novel profibrogenic factor that induces pulmonary fibrosis (PF) through the transforming growth factor-beta 1 (TGF-beta 1)/Smad signaling. Little is known about its effects on PF through the non-Smad signaling, like the mitogen-activated protein kinase (MAPK) pathway. Therefore, this study aimed to investigate the role of FSTL1 in PF through the MAPK signaling pathway and its mechanisms in lung fibrogenesis. Methods: PF was induced in Fstl1(+/-) and wild-type (WT) C57BL/6 mice with bleomycin. After 14 days, the mice were sacrificed, and lung tissues were stained with hematoxylin and eosin; the hydroxyproline content was measured to confirm PF. The mRNA and protein level of FSTL1 and the change of MAPK phosphorylation were measured by quantitative polymerase chain reaction and Western blotting. The effect of Fstl1 deficiency on fibroblasts differentiation was measured by Western blotting and cell immunofluorescence. MAPK signaling activation was measured by Western blotting in Fstl1(+/-) and WT fibroblasts treated with recombinant human FSTL1 protein. We pretreated mouse lung fibroblast cells with inhibitors of the extracellular signal-regulated kinase (ERK), p38, and Jun N-terminal kinase (JNK) signaling and analyzed their differentiation, proliferation, migration, and invasion by Western blotting, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide analysis, and transwell assays. The Student's t-test was used to compare the differences between two groups. Results: Fstl1 deficiency attenuated phosphorylation of the ERK, p38, and JNK signaling in bleomycin-induced fibrotic lung tissue 14 days after injury (0.67 +/- 0.05 vs. 1.22 +/- 0.03, t = 14.92, P = 0.0001; 0.41 +/- 0.01 vs. 1.15 +/- 0.07; t = 11.19; P = 0.0004; and 0.41 +/- 0.01 vs. 1.07 +/- 0.07, t = 8.92, P = 0.0009; respectively), compared with WT lungs at the same time and in primary lung fibroblasts (0.82 +/- 0.01 vs. 1.01 +/- 0.04, t = 4.06, P = 0.0150; 1.04 +/- 0.03 vs. 1.24 +/- 0.03, t = 4.44, P = 0.0100; and 0.76 +/- 0.05 vs. 0.99 +/- 0.05, t = 4.48, P = 0.0100; respectively), compared with TGF-beta 1-stimulated WT group. Recombinant human FSTL1 protein in lung fibroblasts enhanced TGF-beta 1-mediated phosphorylation of the ERK (1.19 +/- 0.08 vs. 0.55 +/- 0.04, t = 6.99, P = 0.0020), p38 (1.18 +/- 0.04 vs. 0.66 +/- 0.03, t = 11.20, P = 0.0020), and JNK (1.11 +/- 0.01 vs. 0.84 +/- 0.04, t = 6.53, P = 0.0030), compared with the TGF-beta 1-stimulated WT group. Fstl1-deficient fibroblasts showed reduced alpha-smooth muscle actin (alpha-SMA) expression (0.70 +/- 0.06 vs. 1.28 +/- 0.11, t = 4.65, P = 0.0035, compared with the untreated WT group; 1.40 +/- 0.05 vs. 1.76 +/- 0.02, t = 6.31, P = 0.0007; compared with the TGF-beta 1-treated WT group). Compared with the corresponding condition in the control group, the TGF-beta 1/FSTL1-mediated alpha-SMA expression was significantly suppressed by pretreatment with an inhibitor of p38 (0.73 +/- 0.01 vs. 1.13 +/- 0.10, t = 3.92, P = 0.0078) and JNK (0.78 +/- 0.03 vs. 1.08 +/- 0.06, t = 4.40, P = 0.0046) signaling. The proliferation of mouse lung fibroblast cells (MLgs) significantly decreased after treatment of an inhibitor of p38 (0.30 +/- 0.01 vs. 0.46 +/- 0.03, t = 4.64, P = 0.0009), JNK (0.30 +/- 0.01 vs. 0.49 +/- 0.01, t = 12.84, P = 0.0001), and Smad2/3 (0.18 +/- 0.02 vs. 0.46 +/- 0.02, t = 12.69, P = 0.0001) signaling compared with the dimethylsulfoxide group. The migration and invasion cells of MLgs significantly decreased in medium pretreated with an inhibitor of p38 (70.17 +/- 3.28 vs. 116.30 +/- 7.11, t = 5.89, P = 0.0042 for the migratory cells; 19.87 +/- 0.84 vs. 32.70 +/- 0.95, t = 10.14, P = 0.0005 for the invasive cells), JNK (72.30 +/- 3.85 vs. 116.30 +/- 7.11, t = 5.44, P = 0.0056 for the migratory cells; 18.03 +/- 0.94 vs. 32.70 +/- 0.95, t = 11.00, P = 0.0004 for the invasive cells), and Smad2/3 (64.76 +/- 1.41 vs. 116.30 +/- 7.11, t = 7.11, P = 0.0021 for the migratory cells; 18.03 +/- 0.94 vs. 32.70 +/- 0.95, t = 13.29, P = 0.0002 for the invasive cells) signaling compared with the corresponding condition in the dimethylsulfoxide group. Conclusion: FSTL1 affects lung fibroblast differentiation, proliferation, migration, and invasion through p38 and JNK signaling, and in this way, it might influence the development of PF.
引用
收藏
页码:1917 / 1925
页数:9
相关论文
共 32 条
  • [1] Clinical features and outcomes of 210 patients with idiopathic pulmonary fibrosis
    Cai Miaotian
    Zhu Min
    Ban Chengjun
    Su Jin
    Ye Qiao
    Liu Yan
    Zhao Wen
    Wang Chen
    Dai Huaping
    [J]. CHINESE MEDICAL JOURNAL, 2014, 127 (10) : 1868 - 1873
  • [2] Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice
    Dong, Yingying
    Geng, Yan
    Li, Lian
    Li, Xiaohe
    Yan, Xiaohua
    Fang, Yinshan
    Li, Xinxin
    Dong, Siyuan
    Liu, Xue
    Li, Xue
    Yang, Xiuhong
    Zheng, Xiaohong
    Xie, Ting
    Liang, Jiurong
    Dai, Huaping
    Liu, Xinqi
    Yin, Zhinan
    Noble, Paul W.
    Jiang, Dianhua
    Ning, Wen
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2015, 212 (02) : 235 - 252
  • [3] Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
    Engelman, Jeffrey A.
    Chen, Liang
    Tan, Xiaohong
    Crosby, Katherine
    Guimaraes, Alexander R.
    Upadhyay, Rabi
    Maira, Michel
    McNamara, Kate
    Perera, Samanthi A.
    Song, Youngchul
    Chirieac, Lucian R.
    Kaur, Ramneet
    Lightbown, Angela
    Simendinger, Jessica
    Li, Timothy
    Padera, Robert F.
    Garcia-Echeverria, Carlos
    Weissleder, Ralph
    Mahmood, Umar
    Cantley, Lewis C.
    Wong, Kwok-Kin
    [J]. NATURE MEDICINE, 2008, 14 (12) : 1351 - 1356
  • [4] Follistatin like-1 aggravates silicainduced mouse lung injury
    Fang, Yinshan
    Zhang, Si
    Li, Xiaohe
    Jiang, Fangxin
    Ye, Qiao
    Ning, Wen
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [5] MEK inhibition suppresses the development of lung fibrosis in the bleomycin model
    Galuppo, Maria
    Esposito, Emanuela
    Mazzon, Emanuela
    Di Paola, Rosanna
    Paterniti, Irene
    Impellizzeri, Daniela
    Cuzzocrea, Salvatore
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2011, 384 (01) : 21 - 37
  • [6] Down-regulation of USP13 mediates phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis
    Geng, Jing
    Huang, Xiaoxi
    Li, Ying
    Xu, Xuefeng
    Li, Shuhong
    Jiang, Dingyuan
    Liang, Jiurong
    Jiang, Dianhua
    Wang, Chen
    Dai, Huaping
    [J]. RESPIRATORY RESEARCH, 2015, 16
  • [7] Follistatin-like 1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling antagonist in controlling mouse lung development
    Geng, Yan
    Dong, Yingying
    Yu, Mingyan
    Zhang, Long
    Yan, Xiaohua
    Sun, Jingxia
    Qiao, Long
    Geng, Huixia
    Nakajima, Masahiro
    Furuichi, Tatsuya
    Ikegawa, Shiro
    Gao, Xiang
    Chen, Ye-Guang
    Jiang, Dianhua
    Ning, Wen
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (17) : 7058 - 7063
  • [8] EFFECT OF ANTIBODY TO TRANSFORMING GROWTH-FACTOR-BETA ON BLEOMYCIN-INDUCED ACCUMULATION OF LUNG COLLAGEN IN MICE
    GIRI, SN
    HYDE, DM
    HOLLINGER, MA
    [J]. THORAX, 1993, 48 (10) : 959 - 966
  • [9] Knockdown of FSTL1 inhibits oxLDL-induced inflammation responses through the TLR4/MyD88/NF-κB and MAPK
    Guo, Junxia
    Liang, Wanqian
    Li, Jianhua
    Long, Jingning
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 478 (04) : 1528 - 1533
  • [10] Regulation of pulmonary fibrosis by chemokine receptor CXCR3
    Jiang, DH
    Liang, JR
    Hodge, J
    Lu, B
    Zhu, Z
    Yu, S
    Fan, J
    Gao, YF
    Yin, ZN
    Homer, R
    Gerard, C
    Noble, PW
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (02) : 291 - 299